Open AccessClinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
Author(s) -
Kentaro Yamada,
Tsunaki Sawada,
Masanao Nakamura,
Takeshi Yamamura,
Keisuke Maeda,
Eri Ishikawa,
Tadashi Iida,
Yasuyuki Mizutani,
Naomi Kakushima,
Takuya Ishikawa,
Kazuhiro Furukawa,
Eizaburo Ohno,
Takashi Honda,
Hiroki Kawashima,
Masatoshi Ishigami,
Satoshi Furune,
Takashi Hase,
Kenji Yokota,
Osamu Maeda,
Naozumi Hashimoto,
Masashi Akiyama,
Yuichi Ando,
Mitsuhiro Fujishiro
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i41.7190
Subject(s) - medicine , adverse effect , cancer , antibody , proportional hazards model , immune system , gastroenterology , nivolumab , survival analysis , incidence (geometry) , oncology , immunology , immunotherapy , physics , optics
Despite the popularity of immune checkpoint inhibitors (ICIs) in the treatment of advanced cancer, patients often develop gastrointestinal (GI) and non-GI immune-related adverse events (irAEs). The clinical characteristics and survival outcomes of GI-irAEs have not been fully elucidated in previous reports. This necessitates the evaluation of the impact of GI-irAEs on patients receiving ICI treatment.